CTOs on the Move

FLX Bio

www.flxbio.com

 
FLX Bio, Inc. is a biotechnology company focused on the discovery and development of novel therapies that will improve and prolong the lives of people with cancer. The company is targeting key cancer pathways with its clinical-stage program, FLX925, and building a pipeline of immuno-oncology oral medicines designed to activate a patient`s own immune system to eradicate cancer.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.flxbio.com
  • 561 Eccles Avenue
    South San Francisco, CA USA 94080
  • Phone: 650.489.9000

Executives

Name Title Contact Details

Funding

FLX Bio raised $50M on 04/26/2016
FLX Bio raised $60M on 12/21/2017
FLX Bio raised $37M on 06/18/2019

Similar Companies

CNS Therapeutics

CNS Therapeutics is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

United Review Services

United Review Services is a Piscataway, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Abivax

Abivax is developing therapies that modulate the body`s natural immune system machinery. A clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to develop drug candidates to treat inflammatory diseases, viral diseases and liver cancer. Abivax is based on innovative research driven by the idea of modulating the body`s natural immune system mechanisms to treat diseases.

Kallyope

At Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the gut informs our brains about our well-being, metabolism, and nutritional state. The gut-brain axis—the communication highway between our gut and our brain—offers an unprecedented opportunity to access and influence brain centers involved in fundamental human processes. An understanding of the biology mediated by the gut and gut-brain circuits will change the way we think about food, nutrition, and human physiology. Founded and headquartered in New York City, we are developing an industry-leading platform to harness the gut-brain axis. Our cross-disciplinary biotechnology team will integrate cutting-edge technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that will lead to transformational therapeutics and consumer products to improve human health and nutrition.

Forty Seven

With a passion for pioneering breakthrough solutions, we are committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity.